Quantifying the ROI of using digital endpoints

October 14, 2024

“Collaboration in the development of digital endpoints can spread both cost and risk to further increase absolute value for every organization. If going at it alone returns substantive value, think of the value we can achieve by going at it together.”

Joseph A. DiMasi, Ph.D., Director of Economic Analysis and Research Associate Professor, Tufts Center for the Study of Drug Development

Tufts Center for the Study of Drug Development (CSDD), Digital Medicine Society (DiMe), and other industry leaders combined forces to take on research that had never been done before: Quantifying the financial costs and benefits associated with using digital endpoints. The results empower decision-makers and digital health innovators with the evidence of substantial value and return on investment (ROI) they need to invest in digital endpoints and advance clinical research.

Key findings

Enhanced efficiency: Digital endpoints significantly shorten trial phases and permit smaller trial enrollment sizes
Financial gains: Phase 3 trials showed an increase in eNPV between $24M and $40M per indication
High ROI: Returns on investment range from 4 to 6 times the cost of implementation